Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
366 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (58)
  • (-) Currently Recruiting (4)
  • Closed (54)

Medical Condition

  • Show all (366)
  • Addiction (2)
  • Allergy, Asthma, & Immunology (1)
  • (-) Autoimmune Disorders (2)
  • Blood Disorders (1)
  • Bone & Muscle (2)
  • Cancer (109)
    • Bladder Cancer (1)
    • Brain Cancer (9)
    • Breast Cancer (7)
    • Gastrointestinal (3)
    • Gynecologic Cancer (9)
    • Kidney Cancer (1)
    • Leukemia (8)
    • Liver Cancer (2)
    • Lung Cancer (6)
    • Lymphoma (12)
    • Multiple Myeloma (8)
    • Pancreatic Cancer (7)
    • Prostate Cancer (6)
    • (-) Skin Cancer (2)
      • Melanoma (2)
  • Child Development (1)
  • COVID-19 (Coronavirus) (10)
  • Diabetes (9)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (45)
  • Heart Disease (25)
  • Infectious Disease (12)
  • Liver Disease (14)
  • Lung Disease (3)
  • Neurological Disorders (45)
  • Nutrition (1)
  • Obesity (8)
  • Obstetrics & Gynecology (12)
  • Pediatrics (26)
  • Psychiatric Disorders (8)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
Displaying 1 - 4 of 4

Study of DYP688 in Patients with Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to identify the safest and most tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ/11). Metastatic means the…
Read More

Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Read More

CONQUER Registry to Track Disease Progression in Systemic Sclerosis (Scleroderma)

Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
The purpose of this study is to develop a cohort of patients with early scleroderma and to collect data on clinical outcomes, radiological tests, laboratory tests, and to obtain biological specimens for testing.
Read More

Genome Research in African American Scleroderma Patients (GRASP Study)

Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
This research is being done to determine how variations in genes may explain the different risks to develop scleroderma (or CREST) seen in African American patients compared to other populations. People who are African American with scleroderma (or CREST) may join. This research involves a blood draw and physical exams.
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science